RBSH Stock Chart & Stats
<$0.01
<$0.01(9900.00%)
At close: 4:00 PM EST
<$0.01
<$0.01(9900.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume402.00
Average Volume (3M)N/A
Market Cap
$3.21K
Enterprise Value$308.21K
Total Cash (Recent Filing)$5.00K
Total Debt (Recent Filing)$310.00K
Price to Earnings (P/E)―
Beta-252.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding32,132,908
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.05
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap95.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RBSH FAQ
What was Rebus Holdings’s price range in the past 12 months?
Currently, no data Available
What is Rebus Holdings’s market cap?
Rebus Holdings’s market cap is $3.21K.
When is Rebus Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rebus Holdings’s earnings last quarter?
Currently, no data Available
Is Rebus Holdings overvalued?
According to Wall Street analysts Rebus Holdings’s price is currently Overvalued.
Does Rebus Holdings pay dividends?
Rebus Holdings does not currently pay dividends.
What is Rebus Holdings’s EPS estimate?
Rebus Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rebus Holdings have?
Rebus Holdings has 32,132,908 shares outstanding.
What happened to Rebus Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rebus Holdings?
Currently, no hedge funds are holding shares in RBSH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rebus Holdings
Rebus Holdings, Inc. is dedicated to pioneering highly targeted therapies for oncology. Its flagship investigational product, RT-AR001, operates as an adenosine receptor antagonist. This compound, when administered directly into cancerous growths, is engineered to diminish tumor invasion and improve therapeutic efficacy. The corporation was established in 2003 and maintains its headquarters in Westlake Village, California.
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---